Inclusion Criteria:
* Participant must be informed of the nature of the study and voluntarily agree to participate by signing an informed consent form prior to any study-specific procedures.
* Participant must be a healthy male, aged 18 to 70 years (inclusive) at the time of dosing.
* Participant must be judged by the Investigator or designee to be in good general health, as documented by medical history, physical examination, clinical laboratory tests, vital signs, and 12-lead electrocardiogram (ECG). Any deviations from normal ranges must be assessed and deemed not clinically significant by the Investigator or designee.
* Participant must have a creatinine clearance (CrCl) value greater than 80 mL/min, as calculated by the Cockcroft-Gault equation.
* Participant must agree to practice an acceptable method of contraception throughout the clinical trial, as outlined in the protocol.
Exclusion Criteria:
* Unwilling or unable to comply with study procedures.
* Use of any investigational drug (except Hezkue/Hezkue Turbo) within 30 days prior to dosing.
* History of significant renal, hepatic, cardiovascular (including orthostatic hypotension), psychiatric, neoplastic, infectious disease, or diabetes mellitus.
* Clinically significant abnormal lab results, vital signs, or ECGs.
* Any hepatic impairment or abnormal liver function tests.
* Positive test for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
* Clinically significant illness within 28 days prior to dosing.
* Known hypersensitivity to sildenafil, tadalafil, vardenafil, or any component of the investigational product (e.g., peppermint oil).
* History of significant food or drug allergies.
* History of drug abuse within the past year or positive drug screen at screening.
* Regular alcohol consumption exceeding 15 units per week.
* Use of CYP450 enzyme inhibitors within 14 days prior to dosing.
* Use of CYP450 enzyme inducers or St. John's Wort within 28 days prior to dosing.
* Blood donation or significant blood loss within 3 months before screening.
* Plasma donation within 14 days prior to first dose.
* Inadequate venous access for repeated blood sampling.
* Difficulty fasting or inability to consume standardized meals.
* Intolerance to fatty foods or inability to consume a high-fat, high-calorie breakfast.
* Difficulty swallowing.
* Regular use of tobacco or nicotine products within 4 weeks prior to screening.
* Major surgery within 3 months or minor surgery within 1 month before screening.
* Considered unsuitable for study participation by the Investigator.
* Institutionalized status.
* Use of hormone replacement therapy within 6 months prior to dosing.
* Consumption of Seville oranges, grapefruit, or pomelo within 7 days prior to dosing.
* Consumption of caffeine, xanthine-containing products, or poppy seeds within 48 hours prior to dosing.
* Receipt of a COVID-19 vaccine within 3 days prior to dosing.
* Presence of braces, retainers, dentures, partial dentures, or tongue piercings.
* Use of nitric oxide donors, organic nitrates/nitrites, antihypertensive medications, or PDE5 inhibitors within 14 days of dosing.
* Blood pressure or heart rate outside acceptable ranges:
* Systolic BP \<90 or \>140 mmHg
* Diastolic BP \<50 or \>90 mmHg
* Heart rate \<50 or \>100 bpm
